Metalloproteases and tendinopathy

Muscles, Ligaments and Tendons Journal

Volumn 3, Issue 1, 2013, Pages 51-57

  Del Buono, Angelo ^a   Oliva, Francesco ^b   Osti, Leonardo ^c   Maffulli, Nicola ^d,e  

^a UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c HESPERIA HOSPITAL   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

Author keywords

Metalloproteases; Tendinopathy; Tendon healing

Indexed keywords

EID: 84887135964     PISSN: None     EISSN: 22404554     Source Type: Journal    
DOI: 10.11138/mltj/2013.3.1.051     Document Type: Review

References (98)

1. Maffulli N, Del Buono A. Platelet plasma rich products in musculoskeletal medicine: Any evidence? The Surgeon 2012; 10:148-150.
2. Longo UG, Ronga M, Maffulli N. Achilles tendinopathy. Sports Med Arthrosc 2009; 17: 112-126.
3. Del Buono A, Battery L, Denaro V, Maccauro G, Maffulli N. Tendinopathy and inflammation: some truths. Int J Immunopathol Pharmacol 2011; 24(1 Suppl 2):45-50.
4. Del Buono A, Papalia R, Denaro V, Maccauro G, Maffulli N. Platelet rich plasma and tendinopathy: state of the art. Int J Immunopathol Pharmacol 2011; 24 (1 Suppl 2):79-83.
5. Fu SC, Chan BP, Wang W, Pau HM, Chan KM, Rolf CG. Increased expression of matrix metalloproteinase 1 (MMP1) in 11 patients with patellar tendinosis. Acta Orthop Scand 2002; 73:658-662.
6. Riley G. The pathogenesis of tendinopathy. A molecular perspective. Rheumatology (Oxford) 2004; 43:131-142.
7. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993; 4:197-250.
8. Brown PD. Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 1997; 14:1-10.
9. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6: 199-213.
10. Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
11. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (review). Int J Mol Med 2000; 6:391-407.
12. Vincenti MP. The matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 2001; 151:121-148.
13. Hellio Le Graverand MP, Eggerer J, Sciore P, Reno C, Vignon E, Otterness I, Hart DA. Matrix metalloproteinase-13 expression in rabbit knee joint connective tissues: influence of maturation and response to injury. Matrix Biol 2000; 19:431-441.
14. Kawahara E, Okada Y, Nakanishi I, Iwata K, Kojima S, Kumagai S, Yamamoto E. The expression of invasive behavior of differentiated squamous carcinoma cell line evaluated by an in vitro invasion model. Jpn J Cancer Res 1993; 84:409-418.
15. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6:121-125.
16. Goupille P, Jayson MI, Valat JP, Freemont AJ. Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine (Phila Pa 1976) 1998; 23:1612-1626.
17. Matsui Y, Maeda M, Nakagami W, Iwata H. The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation. Spine (Phila Pa 1976) 1998; 23:863-868; discussion 868-869.
18. Del Buono A, Denaro V, Maffulli N. Genetic susceptibility to aseptic loosening following total hip arthroplasty: a systematic review. Br Med Bull 2012;101:39-55.
19. Takagi M, Santavirta S, Ida H, Ishii M, Mandelin J, Konttinen YT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. Clin Orthop Relat Res 1998:35-45.
20. Bramono DS, Richmond JC, Weitzel PP, Kaplan DL, Altman GH. Matrix metalloproteinases and their clinical applications in orthopaedics. Clin Orthop Relat Res 2004:272-285.
21. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
22. Dalton S, Cawston TE, Riley GP, Bayley IJ, Hazleman BL. Human shoulder tendon biopsy samples in organ culture produce procollagenase and tissue inhibitor of metalloproteinases. Ann Rheum Dis 1995; 54:571-577.
23. Jhingan S, Perry M, O'Driscoll G, Lewin C, Teatino R, Malliaras P, Maffulli N, Morrissey D. Thicker Achilles tendons are a risk factor to develop Achilles tendinopathy in elite professional soccer players. Muscles, Ligaments and Tendons Journal 2011; 1:51-56.
24. Del Buono A, Oliva F, Longo U, Rodeo S, Orchard J, Denaro V, Maffulli N. Metalloproteases and rotator cuff disease. J Shoulder Elbow Surg 2012; 21:200-208.
25. Merolla G, Paladini P, Saporito M, Porcellini G. Conservative management of rotator cuff tears: literature review and proposal for a prognostic Prediction Score. Muscles, Ligaments and Tendons Journal 2011; 1:12-19.
26. Mandal M, Mandal A, Das S, Chakraborti T, Sajal C. Clinical implications of matrix metalloproteinases. Mol Cell Biochem 2003; 252:305-329.
27. Pearce WH, Shively VP. Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann N Y Acad Sci 2006; 1085:117-132.
28. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci USA 1962; 48:1014-1022.
29. Foos MJ, Hickox JR, Mansour PG, Slauterbeck JR, Hardy DM. Expression of matrix metalloprotease and tissue inhibitor of metalloprotease genes in human anterior cruciate ligament. J Orthop Res 2001; 19:642-649.
30. Al-Sadi O, Schulze-Tanzil G, Kohl B, Lohan A, Lemke M, Ertel W, John T. Tenocytes, pro-inflammatory cytokines and leukocytes: a relationship? Muscles, Ligaments and Tendons Journal 2011; 1:68-76.
31. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-635.
32. van Meurs J, van Lent P, Stoop R, Holthuysen A, Singer I, Bayne E, Mudgett J, Poole R, Billinghurst C, van der Kraan P, Buma P, van den Berg W. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum 1999; 42:2074-2084.
33. Wildemann B, Klatte F. Biological aspects of rotator cuff healing. Muscles, Ligaments and Tendons Journal 2011; 1:161-168.
34. Corps AN, Curry VA, Buttle DJ, Hazleman BL, Riley GP. Inhibition of interleukin-1beta-stimulated collagenase and stromelysin expression in human tendon fibroblasts by epigallocatechin gallate ester. Matrix Biol 2004; 23:163-169.
35. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/ CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87:361-368.
36. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93:178-193.
37. Kossakowska AE, Edwards DR, Prusinkiewicz C, Zhang MC, Guo D, Urbanski SJ, Grogan T, Marquez LA, Janowska-Wieczorek A. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 1999; 94:2080-2089.
38. Meller D, Li DQ, Tseng SC. Regulation of collagenase, stromelysin, and gelatinase B in human conjunctival and conjunctivochalasis fibroblasts by interleukin-1beta and tumor necrosis factor-alpha. Invest Ophthalmol Vis Sci 2000; 41:2922-2929.
39. Giai Via A, Frizziero A, Oliva F. Biological properties of mesenchymal Stem Cells from different sources. Muscles, Ligaments and Tendons Journal 2012; 2:154-162.
40. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 252:C1-9.
41. Cawston TE, Murphy G, Mercer E, Galloway WA, Hazleman BL, Reynolds JJ. The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J 1983; 211:313-318.
42. Ahonen M, Baker AH, Kahari VM. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58:2310-2315.
43. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-3727.
44. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006; 25:99-113.
45. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69:562-573.
46. Gueders MM, Balbin M, Rocks N, Foidart JM, Gosset P, Louis R, Shapiro S, Lopez-Otin C, Noel A, Cataldo DD. Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation. J Immunol 2005; 175:2589-2597.
47. Owen CA, Hu Z, Lopez-Otin C, Shapiro SD. Membranebound matrix metalloproteinase-8 on activated polymorphonuclear cells is a potent, tissue inhibitor of metalloproteinase-resistant collagenase and serpinase. J Immunol 2004; 172:7791-7803.
48. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98:621-628.
49. Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther 2005; 7:160-169.
50. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12:12-26.
51. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9:63-79.
52. Emingil G, Atilla G, Sorsa T, Luoto H, Kirilmaz L, Baylas H. The effect of adjunctive low-dose doxycycline therapy on clinical parameters and gingival crevicular fluid matrix metalloproteinase-8 levels in chronic periodontitis. J Periodontol 2004; 75:106-115.
53. O'Dell JR, Elliott JR, Mallek JA, Mikuls TR, Weaver CA, Glickstein S, Blakely KM, Hausch R, Leff RD. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone. Arthritis Rheum 2006; 54:621-627.
54. Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. J Clin Periodontol 2005; 32:1163-1169.
55. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 2007; 6:480-498.
56. Heikkila P, Teronen O, Moilanen M, Konttinen YT, Hanemaaijer R, Laitinen M, Maisi P, van der Pluijm G, Bartlett JD, Salo T, Sorsa T. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinasetype plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 2002; 13:245-254.
57. de Mos M, van El B, DeGroot J, Jahr H, van Schie HT, van Arkel ER, Tol H, Heijboer R, van Osch GJ, Verhaar JA. Achilles tendinosis: changes in biochemical composition and collagen turnover rate. Am J Sports Med 2007; 35:1549-1556.
58. Raleigh SM, van der Merwe L, Ribbans WJ, Smith RK, Schwellnus MP, Collins M. Variants within the MMP3 gene are associated with Achilles tendinopathy: possible interaction with the COL5A1 gene. Br J Sports Med 2009; 43:514-520.
59. Magra M, Maffulli N. Matrix metalloproteases: a role in overuse tendinopathies. Br J Sports Med 2005; 39:789-791.
60. Orchard J, Massey A, Brown R, Cardon-Dunbar A, Hofmann J. Successful management of tendinopathy with injections of the MMP-inhibitor aprotinin. Clin Orthop Relat Res 2008; 466:1625-1632.
61. Brown R, Orchard J, Kinchington M, Hooper A, Nalder G. Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. Br J Sports Med 2006; 40:275-279.
62. Beierlein W, Scheule AM, Dietrich W, Ziemer G. Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions. Ann Thorac Surg 2005; 79:741-748.
63. Dietrich W, Spath P, Zuhlsdorf M, Dalichau H, Kirchhoff PG, Kuppe H, Preiss DU, Mayer G. Anaphylactic reactions to aprotinin reexposure in cardiac surgery: relation to antiaprotinin immunoglobulin G and E antibodies. Anesthesiology 2001; 95:64-71; discussion 5A-6A.
64. Maffulli N, Longo UG, Denaro V. Novel approaches for the management of tendinopathy. J Bone Joint Surg Am; 92:2604-2613.
65. Alfredson H. The chronic painful Achilles and patellar tendon: research on basic biology and treatment. Scand J Med Sci Sports 2005; 15:252-259.
66. Schubert TE, Weidler C, Lerch K, Hofstadter F, Straub RH. Achilles tendinosis is associated with sprouting of substance P positive nerve fibres. Ann Rheum Dis 2005; 64: 1083-1086.
67. Cury PR, Canavez F, de Araujo VC, Furuse C, de Araujo NS. Substance P regulates the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in cultured human gingival fibroblasts. J Periodontal Res 2008; 43:255-260.
68. Burssens P, Steyaert A, Forsyth R, van Ovost EJ, Depaepe Y, Verdonk R. Exogenously administered substance P and neutral endopeptidase inhibitors stimulate fibroblast proliferation, angiogenesis and collagen organization during Achilles tendon healing. Foot Ankle Int 2005; 26:832-839.
69. Steyaert AE, Burssens PJ, Vercruysse CW, Vanderstraeten GG, Verbeeck RM. The effects of substance P on the biomechanic properties of ruptured rat Achilles' tendon. Arch Phys Med Rehabil 2006; 87:254-258.
70. Lo IK, Marchuk LL, Hollinshead R, Hart DA, Frank CB. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase mRNA levels are specifically altered in torn rotator cuff tendons. Am J Sports Med 2004; 32:1223-1229.
71. Riley GP, Harrall RL, Constant CR, Chard MD, Cawston TE, Hazleman BL. Glycosaminoglycans of human rotator cuff tendons: changes with age and in chronic rotator cuff tendinitis. Ann Rheum Dis 1994; 53:367-376.
72. Blevins FT, Djurasovic M, Flatow EL, Vogel KG. Biology of the rotator cuff tendon. Orthop Clin North Am 1997; 28:1-16.
73. Fan L, Sarkar K, Franks DJ, Uhthoff HK. Estimation of total collagen and types I and III collagen in canine rotator cuff tendons. Calcif Tissue Int 1997; 61:223-229.
74. Knauper V, Lopez-Otin C, Smith B, Knight G, Murphy G. Biochemical characterization of human collagenase-3. J Biol Chem 1996; 271:1544-1550.
75. Vaalamo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kahari VM, Saarialho-Kere U. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997; 109:96-101.
76. Riley GP, Curry V, DeGroot J, van El B, Verzijl N, Hazleman BL, Bank RA. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol 2002; 21:185-195.
77. Yoshihara Y, Hamada K, Nakajima T, Fujikawa K, Fukuda H. Biochemical markers in the synovial fluid of glenohumeral joints from patients with rotator cuff tear. J Orthop Res 2001; 19:573-579.
78. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, Duffin KL. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58:2420-2431.
79. Choi HR, Kondo S, Hirose K, Ishiguro N, Hasegawa Y, Iwata H. Expression and enzymatic activity of MMP-2 during healing process of the acute supraspinatus tendon tear in rabbits. J Orthop Res 2002; 20:927-933.
80. Oshiro W, Lou J, Xing X, Tu Y, Manske PR. Flexor tendon healing in the rat: a histologic and gene expression study. J Hand Surg Am 2003; 28:814-823.
81. Pasternak B, Fellenius M, Aspenberg P. Doxycycline impairs tendon repair in rats. Acta Orthop Belg 2006; 72:756-760.
82. Pasternak B, Schepull T, Eliasson P, Aspenberg P. Elevation of systemic matrix metalloproteinases 2 and 7 and tissue inhibitor of metalloproteinase 2 in patients with a history of Achilles tendon rupture: pilot study. Br J Sports Med; 44:669-672.
83. Arnoczky SP, Lavagnino M, Egerbacher M, Caballero O, Gardner K. Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study. Am J Sports Med 2007; 35:763-769.
84. Demirag B, Sarisozen B, Ozer O, Kaplan T, Ozturk C. Enhancement of tendon-bone healing of anterior cruciate ligament grafts by blockage of matrix metalloproteinases. J Bone Joint Surg Am 2005; 87:2401-2410.
85. Wada A, Kubota H, Miyanishi K, Hatanaka H, Miura H, Iwamoto Y. Comparison of postoperative early active mobilization and immobilization in vivo utilising a four-strand flexor tendon repair. J Hand Surg Br 2001; 26:301-306.
86. Yildirim Y, Kara H, Cabukoglu C, Esemenli T. Suture holding capacity of the Achilles tendon during the healing period: an in vivo experimental study in rabbits. Foot Ankle Int 2006; 27:121-124.
87. McDowell CL, Marqueen TJ, Yager D, Owen J, Wayne JS. Characterization of the tensile properties and histologic/biochemical changes in normal chicken tendon at the site of suture insertion. J Hand Surg Am 2002; 27:605-614.
88. Pasternak B, Missios A, Askendal A, Tengvall P, Aspenberg P. Doxycycline-coated sutures improve the suture-holding capacity of the rat Achilles tendon. Acta Orthop 2007; 78:680-686.
89. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101:1478-1487.
90. Bond M, Murphy G, Bennett MR, Newby AC, Baker AH. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002; 277:13787-13795.
91. Smith MR, Kung H, Durum SK, Colburn NH, Sun Y. TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997; 9:770-780.
92. Wallace JA, Alexander S, Estrada EY, Hines C, Cunningham LA, Rosenberg GA. Tissue inhibitor of metalloproteinase-3 is associated with neuronal death in reperfusion injury. J Cereb Blood Flow Metab 2002; 22:1303-1310.
93. Bedi A, Kovacevic D, Hettrich C, Gulotta LV, Ehteshami JR, Warren RF, Rodeo SA. The effect of matrix metalloproteinase inhibition on tendon-to-bone healing in a rotator cuff repair model. J Shoulder Elbow Surg; 19:384-391.
94. Apte SS, Fukai N, Beier DR, Olsen BR. The matrix metalloproteinase-14 (MMP-14) gene is structurally distinct from other MMP genes and is co-expressed with the TIMP-2 gene during mouse embryogenesis. J Biol Chem 1997; 272:25511-25517.
95. Gulotta LV, Kovacevic D, Montgomery S, Ehteshami JR, Packer JD, Rodeo SA. Stem cells genetically modified with the developmental gene MT1-MMP improve regeneration of the supraspinatus tendon-to-bone insertion site. Am J Sports Med; 38:1429-1437.
96. Kinoh H, Sato H, Tsunezuka Y, Takino T, Kawashima A, Okada Y, Seiki M. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 1996; 109(Pt 5):953-959.
97. Cohen DB, Kawamura S, Ehteshami JR, Rodeo SA. Indomethacin and celecoxib impair rotator cuff tendon-tobone healing. Am J Sports Med 2006; 34:362-369.
98. Bedi A, Fox AJ, Kovacevic D, Deng XH, Warren RF, Rodeo SA. Doxycycline-mediated inhibition of matrix metalloproteinases improves healing after rotator cuff repair. Am J Sports Med; 38:308-317.